KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Other Non Operating Income readings, the most recent being -$4.3 million for Q1 2026.

  • On a quarterly basis, Other Non Operating Income fell 146.73% to -$4.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$88.2 million, a 43.78% increase, with the full-year FY2025 number at $5.2 million, up 102.88% from a year prior.
  • Other Non Operating Income hit -$4.3 million in Q1 2026 for Alnylam Pharmaceuticals, down from -$3.4 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $55.0 million in Q4 2022 to a low of -$80.8 million in Q4 2024.
  • Median Other Non Operating Income over the past 5 years was -$29.5 million (2024), compared with a mean of -$29.4 million.
  • The widest YoY moves for Other Non Operating Income: up 2783.8% in 2022, down 382.89% in 2022.
  • Alnylam Pharmaceuticals' Other Non Operating Income stood at $55.0 million in 2022, then crashed by 136.99% to -$20.4 million in 2023, then crashed by 297.26% to -$80.8 million in 2024, then skyrocketed by 95.84% to -$3.4 million in 2025, then decreased by 27.83% to -$4.3 million in 2026.
  • The last three reported values for Other Non Operating Income were -$4.3 million (Q1 2026), -$3.4 million (Q4 2025), and -$74.1 million (Q3 2025) per Business Quant data.